Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Database
Publication year range
1.
Vopr Virusol ; 65(2): 87-94, 2020.
Article in Russian | MEDLINE | ID: mdl-32515564

ABSTRACT

INTRODUCTION: Interferons (IFN) and IFN inducers are effective in suppressing viral reproduction and correcting of the innate immunity mechanisms. The aim of the study was to test the hypothesis of the possible involvement of the IFN inducer CelAgrip (CA) as an activator or suppressor of antiviral effects in Burkitt's lymphoma (LB) cell cultures with different ability to produce Epstein-Barr virus antigens (EBV). MATERIAL AND METHODS: The kinetic analysis of the dynamics of reactive oxygen species (ROS) production and determination of gene group expression by real-time PCR in response to CA treatment were done in human cell lines LB P3HR-1 and Namalva, spontaneously producing and not producing EBV antigens. RESULTS AND DISCUSSION: When treating CA in Namalva cells, a decrease in the ROS activation index was found; in P3HR-1 cells, an increase was observed. After treatment with CA, there was no reliable activation of the IFN-α, IFN-ß and IFN-λ genes in Namalva cells, but the expression of the ISG15 and P53(TP53) genes was increased more than 1200 times and 4.5 times, respectively. When processing the CA of P3HR-1 cells, the expression of IFN-α genes increased by more than 200 times, IFN-λ - 100 times, and the ISG15 gene - 2.2 times. The relationship between IFN-inducing action of CA and the activity of ISG15 and ROS in LB cell cultures producing and not producing EBV antigens is supposed. CONCLUSION: In Namalva cells that do not produce EBV antigens the treatment of CA results in suppression of ROS generation and activation of the expression of genes ISG15 and P53 (TP53); in P3HR-1 cells producing EBV antigens, the opposite picture is observed - the formation of ROS and the expression of the IFN-α and IFN-λ genes are activated and the activity of the ISG15 and P53 (TP53) genes is suppressed.


Subject(s)
Burkitt Lymphoma/virology , Herpesvirus 4, Human/genetics , Interferon-alpha/genetics , Interferon-beta/genetics , Interferon-gamma/genetics , Antigens, Viral/genetics , Antigens, Viral/immunology , Antigens, Viral/pharmacology , Antiviral Agents/pharmacology , Burkitt Lymphoma/genetics , Burkitt Lymphoma/immunology , Cytokines/genetics , Gene Expression Regulation/immunology , Gene Expression Regulation, Neoplastic , Herpesvirus 4, Human/pathogenicity , Humans , Immunity, Innate/genetics , Kinetics , Reactive Oxygen Species/chemistry , Tumor Suppressor Protein p53/genetics , Ubiquitins/genetics
2.
Vopr Virusol ; 65(5): 284-293, 2020 Nov 15.
Article in Russian | MEDLINE | ID: mdl-33533212

ABSTRACT

INTRODUCTION: Medicines from the group of interferon inducers (IFNs) "swith on" the synthesis of type 1 interferons (IFN-I) and induce the expression of IFN-stimulated genes (ISGs) that regulate innate immunity reactions and protect the host from infectious agents and the tumour pathology.The purpose of the study was to determine the role of the drug celagrip (CA) in the activation of innate immunity genes and the effect on the production of reactive oxygen species (ROS) in patients with follicular lymphoma (FL). OBJECTIVES:  to study the intensity of ROS production and the level of expression of the IFN-α2, IFN-λ1, ISG15, BCL2, P53(TP53) and USP18 genes in response to the treatment of blood cells of patients with FL with the preparation of CA. MATERIAL AND METHODS: The study involved primary cancer patients diagnosed with follicular lymphoma (FL) and healthy volunteers. A kinetic analysis of the dynamics of production of reactive oxygen species (ROS) was performed in whose blood cells, and the expression of the group of genes was determined by real-time PCR in response to CA processing. RESULTS AND DISCUSSION: ROS production by blood cells of patients with FL and volunteers in the presence of CA significantly decreased (P < 0.05). The level of gene expression of ISG15, P53(TR53) and USP 18 in the group of patients with FL was significantly higher than that in the group of volunteers. When treating blood cells with CA, it becomes possible to divide patients with FL into groups with a positive and negative response in accordance with the level of expression of the USP18 gene. We divided FL patients into groups with a positive and negative response in accordance with the level of USP18 gene expression after treatment of blood cells with CA. CONCLUSIONS: The CA drug reduces the production of ROS and simultaneously stimulates the activity of the innate immunity genes ISG15, P53(TP53) and USP18 in the blood cells of patients with FL.


Subject(s)
Antiviral Agents/administration & dosage , Cytokines/genetics , Lymphoma, Follicular/drug therapy , Tumor Suppressor Protein p53/genetics , Ubiquitin Thiolesterase/genetics , Ubiquitins/genetics , Adult , Aged , Antiviral Agents/adverse effects , Female , Gene Expression Regulation, Neoplastic/drug effects , Humans , Immunity, Innate/genetics , Interferon-alpha/genetics , Interferon-gamma/genetics , Kinetics , Lymphoma, Follicular/genetics , Lymphoma, Follicular/virology , Male , Middle Aged , Reactive Oxygen Species/metabolism , Signal Transduction/drug effects
3.
Vopr Virusol ; 64(4): 165-172, 2019.
Article in Russian | MEDLINE | ID: mdl-32163682

ABSTRACT

INTRODUCTION: Cytokines activated in response to immunosuppressive viral infections can directly or indirectly affect the neoplastic transformation of B cells. In this study, we studied a new substance designed to produce the antiviral drug CelAgrip (CA, CelAgripus), which exhibits interferon (IFN) and cytokine-inducing activity and, apparently, can be used as an activator of antiviral immunity. Purpose - is to evaluate the cytokine-regulating effect of CA in Burkitt's lymphoma (LB) cell lines latently infected with the Epstein-Barr virus (EBV). OBJECTIVES: to study the CA-induced expression of the cytokine genes IL-1ß, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12, IL-17, IL-18, IFN-α, IFN -γ, IFN-ß, IFN-λ1, IFN-λ2, IFN-λ3, TNF-α in normal and EBV transformed LB cells. MATERIAL AND METHODS: Cell line: the human embryo fibroblasts (HEF), Namalva, Daudi, Raji, P3HR-1. Preparations: CA, gossypol-acetic acid (GAA), sodium carboxymethyl cellulose (Na-CMC). METHODS: RT-PCR and methods for assessing cytotoxicity (MTT and Scepter 2.0 Merck cell counter). RESULTS: The effect of the CA preparation on the expression of IFN-λ, IL-1ß, IL-6, IL-8 and IL-10 genes was revealed. DISCUSSION: We observed the activation of gene expression of IFN-λ, IL-1ß, IL-6, IL-8 and suppression of IL-10 gene activity when treatment CA of LB cells. CONCLUSION: The substance CA has new effects on the activation of the expression of a number of key cytokine genes in stable Burkitt lymphoma cell lines.


Subject(s)
Burkitt Lymphoma/drug therapy , Cytokines/genetics , Immunity, Innate/drug effects , Virus Diseases/genetics , Antiviral Agents/pharmacology , B-Lymphocytes/drug effects , B-Lymphocytes/immunology , Burkitt Lymphoma/immunology , Burkitt Lymphoma/virology , Cell Line, Tumor , Gene Expression Regulation, Neoplastic/drug effects , Herpesvirus 4, Human/genetics , Herpesvirus 4, Human/pathogenicity , Humans , Immunity, Innate/genetics , Interferon-alpha/genetics , Interferons/genetics , Tumor Necrosis Factor-alpha/genetics , Virus Diseases/virology
4.
Vestn Oftalmol ; 131(4): 49-55, 2015.
Article in Russian | MEDLINE | ID: mdl-26489119

ABSTRACT

UNLABELLED: The problem with post-adenoviral corneal infiltrates is that they cause a significant and persistent decrease in visual function, while corticosteroids in monotherapy bring only temporary improvement. AIM: to perform a comparative evaluation of topical corticosteroids and 0.05% cyclosporine A efficacy in the treatment of post-adenoviral corneal infiltrates on the basis of clinical presentation and local cytokine status. MATERIAL AND METHODS: The study involved two groups of patients after adenoviral keratoconjunctivitis: group 1 (25 patients, 45 eyes) were prescribed a diminishing regimen of corticosteroid eye drops for 12 weeks and corneal protectors; group 2 (24 patients, 42 eyes) received the same treatment as described above plus topical 0.05% cyclosporine A for 6 months. The follow-up period was from 6 to 12 months. Visual acuity measurements, biomicroscopy, and pneumatic tonometry were performed at months 1, 3, and 6. Local cytokine status was assessed by studying cytokine gene expression in cell culture from conjunctival scrapings and cytokines levels in the supernatant. The tests were done before the beginning of the treatment in both groups, at month 1 in group 1, at month 4 in group 2 (i.e. in a month after the cessation of dexamethasone) and also in a group of healthy volunteers (30 persons, 30 eyes). RESULTS: Long-term combined anti-inflammatory therapy with corticosteroids and 0.05% cyclosporine A in patients with post-adenoviral corneal infiltrates has yielded positive clinical results, including a persistent increase in visual acuity and complete resolution of corneal opacities (92.8%). In addition, we revealed a correlation between local cytokine status changes and clinical results. CONCLUSION: The proposed therapeutic regimen enabled complete suppression of residual interferon-α antiviral activity, an increase in interleukin-4 that regulates local humoral immunity, and a decrease (down to a complete suppression) in anti-inflammatory interleukin-2, which is responsible for activation of cell-mediated immunity, thus, resulting in resolution of the immune-mediated inflammation in the cornea.


Subject(s)
Adenovirus Infections, Human/complications , Corneal Diseases , Cyclosporine/administration & dosage , Glucocorticoids/administration & dosage , Keratoconjunctivitis/complications , Administration, Topical , Adult , Cornea/pathology , Corneal Diseases/diagnosis , Corneal Diseases/drug therapy , Corneal Diseases/etiology , Corneal Diseases/immunology , Corneal Diseases/physiopathology , Cytokines/analysis , Drug Monitoring , Female , Humans , Immunosuppressive Agents/administration & dosage , Male , Middle Aged , Treatment Outcome , Visual Acuity
SELECTION OF CITATIONS
SEARCH DETAIL
...